Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID Lead-In)

NCT03759288 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03759288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03759288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID Lead-In)
Lead sponsor
AstraZeneca
Phase
Phase 2/3
Overall status
Terminated
Start date
December 7, 2018
Completion date
October 18, 2023
Enrollment
89 (actual)
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, ibd